We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
EDAP's Avenda Deal for AI-Assisted Cancer Care Likely to Drive Stock
Read MoreHide Full Article
EDAP TMS (EDAP - Free Report) has taken a significant step toward expanding its AI-assisted prostate cancer care through a strategic collaboration with AI healthcare company Avenda Health. This partnership is centered around integrating Avenda's FDA-cleared Unfold AI technology into EDAP’s Focal One robotic high-intensity focused ultrasound (HIFU) platform.
This is expected to create the world’s first AI-assisted Focal One HIFU procedures.
EDAP Stock Movement
Since the announcement on Sept. 19, EDAP shares have remained unchanged. As the application of robotics and AI is increasing enormously in every sphere of healthcare, the company’s initiative to combine the latest technologies into imaging and treatment modalities is witnessing huge market acceptance. The latest collaboration too, if successfully executed, should witness strong market optimism, leading to a rise in stock price.
EDAP Leveraging AI for Precision in Prostate Cancer Treatment
The core of this collaboration lies in Avenda Health’s Unfold AI, an AI-powered platform designed to provide urologists with enhanced tools for cancer detection and treatment planning. By creating 3D patient-specific cancer maps, Unfold AI will help physicians visualize otherwise invisible tumor extents. This capability ensures that cancerous tissue is precisely targeted during ablation procedures while minimizing damage to healthy surrounding tissue.
When combined with EDAP’s Focal One platform, Unfold AI enables more accurate and patient-specific treatment options. This marks a crucial evolution in the capabilities of HIFU technology, further enhancing its precision and oncologic outcomes. Physicians like Dr. Wayne G. Brisbane of UCLA have already noted the seamless integration of these technologies in guiding the ablation process, minimizing risks and improving cancer control.
Image Source: Zacks Investment Research
More on the EDAP-Avenda Partnership Synergy Goal
The partnership between EDAP and Avenda Health aims to bring cutting-edge AI technology to a wider network of urologists and prostate cancer care providers. Avenda, in this regard, emphasized that Unfold AI’s capabilities will complement Focal One, empowering surgeons to map and eradicate tumors with greater confidence and accuracy. This collaboration will not only enhance the efficacy of prostate cancer treatments but also set a new standard in cancer care through AI-driven decision support.
For EDAP, this collaboration represents a strategic advancement in its goal of staying at the forefront of prostate cancer treatment solutions. According to the company, integrating AI into the Focal One platform is a crucial next step, allowing urologists to develop more personalized and precise treatment plans.
Market Prospects in Favor of EDAP
According to a market.us report, global AI In cancer market size is expected to reach around $19.82 billion by 2033 from $985.5 million in 2023, at a CAGR of 35% during the forecast period of 2024 to 2033.
The global AI in cancer treatment market is poised for significant growth, driven by increasing cancer incidence and advancements in AI technology. With over $6 billion invested in AI-based oncology solutions over the past five years, this technology enhances diagnostic accuracy, reduces treatment errors and improves patient outcomes. The rise in FDA approvals for AI-based medical devices, particularly for breast cancer diagnosis, underscores its potential. AI’s ability to process complex datasets reduces healthcare pressure, making it an indispensable tool in modern oncology. This trend is set to continue, fueled by ongoing innovations and expanding healthcare infrastructure.
Shares Comparison
Year to date, shares of EDAP have plummeted 42.2% against the industry’s 9.8% growth.
Estimates for TransMedics’ 2024 earnings per share (EPS) have moved up 2.5% to $1.23 in the past 30 days. Shares of the company have soared 156.5% in the past year compared with the industry’s 17.5% growth. TMDX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 287.50%. In the last reported quarter, it delivered an earnings surprise of 66.67%.
Estimates for AxoGen’s 2024 loss per share have remained constant at 1 cent in the past 30 days. Shares of the company have surged 165.9% in the past year compared with the industry’s 17.6% growth. AXGN’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 96.5%. In the last reported quarter, it delivered an earnings surprise of 200%
Estimates for 2024 OrthoPediatrics’ loss per share have declined to 92 cents from 96 cents in the past 30 days. In the past year, shares of KIDS have lost 0.8% against the industry’s 18.1% growth. In the last reported quarter, KIDS delivered an earnings surprise of 25.81%. Its earnings surpassed estimates in each of the trailing four quarters, the average surprise being 26.81%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
EDAP's Avenda Deal for AI-Assisted Cancer Care Likely to Drive Stock
EDAP TMS (EDAP - Free Report) has taken a significant step toward expanding its AI-assisted prostate cancer care through a strategic collaboration with AI healthcare company Avenda Health. This partnership is centered around integrating Avenda's FDA-cleared Unfold AI technology into EDAP’s Focal One robotic high-intensity focused ultrasound (HIFU) platform.
This is expected to create the world’s first AI-assisted Focal One HIFU procedures.
EDAP Stock Movement
Since the announcement on Sept. 19, EDAP shares have remained unchanged. As the application of robotics and AI is increasing enormously in every sphere of healthcare, the company’s initiative to combine the latest technologies into imaging and treatment modalities is witnessing huge market acceptance. The latest collaboration too, if successfully executed, should witness strong market optimism, leading to a rise in stock price.
EDAP Leveraging AI for Precision in Prostate Cancer Treatment
The core of this collaboration lies in Avenda Health’s Unfold AI, an AI-powered platform designed to provide urologists with enhanced tools for cancer detection and treatment planning. By creating 3D patient-specific cancer maps, Unfold AI will help physicians visualize otherwise invisible tumor extents. This capability ensures that cancerous tissue is precisely targeted during ablation procedures while minimizing damage to healthy surrounding tissue.
When combined with EDAP’s Focal One platform, Unfold AI enables more accurate and patient-specific treatment options. This marks a crucial evolution in the capabilities of HIFU technology, further enhancing its precision and oncologic outcomes. Physicians like Dr. Wayne G. Brisbane of UCLA have already noted the seamless integration of these technologies in guiding the ablation process, minimizing risks and improving cancer control.
Image Source: Zacks Investment Research
More on the EDAP-Avenda Partnership Synergy Goal
The partnership between EDAP and Avenda Health aims to bring cutting-edge AI technology to a wider network of urologists and prostate cancer care providers. Avenda, in this regard, emphasized that Unfold AI’s capabilities will complement Focal One, empowering surgeons to map and eradicate tumors with greater confidence and accuracy. This collaboration will not only enhance the efficacy of prostate cancer treatments but also set a new standard in cancer care through AI-driven decision support.
For EDAP, this collaboration represents a strategic advancement in its goal of staying at the forefront of prostate cancer treatment solutions. According to the company, integrating AI into the Focal One platform is a crucial next step, allowing urologists to develop more personalized and precise treatment plans.
Market Prospects in Favor of EDAP
According to a market.us report, global AI In cancer market size is expected to reach around $19.82 billion by 2033 from $985.5 million in 2023, at a CAGR of 35% during the forecast period of 2024 to 2033.
The global AI in cancer treatment market is poised for significant growth, driven by increasing cancer incidence and advancements in AI technology. With over $6 billion invested in AI-based oncology solutions over the past five years, this technology enhances diagnostic accuracy, reduces treatment errors and improves patient outcomes. The rise in FDA approvals for AI-based medical devices, particularly for breast cancer diagnosis, underscores its potential. AI’s ability to process complex datasets reduces healthcare pressure, making it an indispensable tool in modern oncology. This trend is set to continue, fueled by ongoing innovations and expanding healthcare infrastructure.
Shares Comparison
Year to date, shares of EDAP have plummeted 42.2% against the industry’s 9.8% growth.
Zacks Rank of EDAP and Key Picks
EDAP currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are TransMedics Group (TMDX - Free Report) , AxoGen (AXGN - Free Report) and OrthoPediatrics (KIDS - Free Report) . While TransMedics sports a Zacks Rank #1 (Strong Buy) at present, AxoGen and OrthoPediatrics carry a Zacks Rank #2 (Buy) each. You can see the complete list of today’s Zacks #1 Rank stocks here.
Estimates for TransMedics’ 2024 earnings per share (EPS) have moved up 2.5% to $1.23 in the past 30 days. Shares of the company have soared 156.5% in the past year compared with the industry’s 17.5% growth. TMDX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 287.50%. In the last reported quarter, it delivered an earnings surprise of 66.67%.
Estimates for AxoGen’s 2024 loss per share have remained constant at 1 cent in the past 30 days. Shares of the company have surged 165.9% in the past year compared with the industry’s 17.6% growth. AXGN’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 96.5%. In the last reported quarter, it delivered an earnings surprise of 200%
Estimates for 2024 OrthoPediatrics’ loss per share have declined to 92 cents from 96 cents in the past 30 days. In the past year, shares of KIDS have lost 0.8% against the industry’s 18.1% growth. In the last reported quarter, KIDS delivered an earnings surprise of 25.81%. Its earnings surpassed estimates in each of the trailing four quarters, the average surprise being 26.81%.